Skip to content

Optimizing plasma collection and donor safety – POLITICO – POLITICO Europe

Optimizing plasma collection and donor safety – POLITICO – POLITICO Europe

With a reliance on the U.S. for up to 40 percent of our human blood plasma needs, Europe faces a major challenge: we simply do not collect enough plasma. Some 300,000 rare disease patients depend on plasma-derived medicinal products (PDMPs) to treat a wide range of serious and life-threating conditions, including hemophilia and primary immune deficiency (PID). What’s more, this number is growing fast, as improved diagnostic techniques, heightened awareness of treatable diseases among physicians, and broader indicated use drive growing patient need for PDMPs. Indeed, for many rare disease patients, PDMPs are often the only treatment option to keep patients… 

Read More

Leave a Reply

Your email address will not be published. Required fields are marked *